Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

Systemic Anaplastic Large Cell Lymphoma: later-stage trial registry

1 of 1 indexed Systemic Anaplastic Large Cell Lymphoma trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Systemic Anaplastic Large Cell Lymphoma: 1 US clinical trial tracked, 1 recruiting.

Systemic Anaplastic Large Cell Lymphoma is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Corvus Pharmaceuticals, running 1 of these trials.

Enrollment posture brief

Registry condition systemic-anaplastic-large-cell-lymphoma

OPEN 1 | RECR 100% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Systemic Anaplastic Larg (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Systemic Anaplastic Large Cell Lymphoma

Systemic Anaplastic Large Cell Lymphoma lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Systemic Anaplastic Large Cell Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Systemic Anaplastic Large Cell Lymphoma is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 31

Phase Distribution

PhaseTrial count
Phase 3 1

Top Sponsors

Named interventions

Most-linked intervention names on Systemic Anaplastic Large Cell Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Soquelitinib Drug
1 trials
Pralatrexate Drug
1 trials
Belinostat Drug
1 trials

US sites by state

Facility locations filed on Systemic Anaplastic Large Cell Lymphoma trials. A trial with sites in several states counts in each.

Wisconsin 1 trials
Washington 1 trials
Texas 1 trials
Ohio 1 trials
New York 1 trials
New Jersey 1 trials
North Carolina 1 trials
Missouri 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Systemic Anaplastic Large Cell Lymphoma page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Systemic Anaplastic Large Cell Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Corvus Pharmaceuticals sponsors the most Systemic Anaplastic Large Cell Lymphoma trials on record, review their full trial history before evaluating a specific study. See Corvus Pharmaceuticals's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Systemic Anaplastic Large Cell Lymphoma condition card totals 1 registered trials; most-linked intervention Soquelitinib; top US site state Wisconsin. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.